Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Tivozanib hydrochloride
DRUG
3 trials
Sponsors
AVEO Pharmaceuticals, Inc.
Conditions
Carcinoma, Renal Cell
Hepatic Impairment
Triple Negative Breast Cancer
Phase 1
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
Completed
NCT01631097
AVEO Pharmaceuticals, Inc.
Hepatic Impairment
Start: 2012-05-31
End: 2014-01-31
Target: 44
Updated: 2014-01-27
Phase 2
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Terminated
NCT01745367
AVEO Pharmaceuticals, Inc.
Triple Negative Breast Cancer
Start: 2012-11-30
End: 2014-06-30
Updated: 2020-10-27
Phase 3
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
Completed
NCT02627963
AVEO Pharmaceuticals, Inc.
Carcinoma, Renal Cell
Start: 2016-05-24
End: 2021-06-21
Updated: 2023-07-18
Related Papers
Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.
Journal of Clinical Oncology
2022-06-01
2 citations
Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC.
Journal of Clinical Oncology
2022-02-16
3 citations
349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3
Regular and Young Investigator Award Abstracts
2021-11-01
1 citations
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).
Journal of Clinical Oncology
2021-05-20
2 citations
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.
Journal of Clinical Oncology
2021-05-20
1 citations
TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial.
Journal of Clinical Oncology
2021-05-20
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study
Clinical Genitourinary Cancer
2021-04-03
8 citations
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.
Journal of Clinical Oncology
2021-02-20
2 citations
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study.
Journal of Clinical Oncology
2021-02-20
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
2019-12-03
173 citations
TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Journal of Clinical Oncology
2019-05-20
1 citations
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Journal of Clinical Oncology
2019-03-01
10 citations
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
Journal of Clinical Oncology
2017-05-20
6 citations